INHIBRX BIOSCIENCES INC reported that its experimental combination cancer drug shrank tumors in 48.3% of mid-stage head and neck cancer patients. The trial evaluated INBRX-106 paired with Keytruda against Keytruda alone in 68 patients. The data points toward a competitive profile in a difficult biological target.

Targeting HPV-Positive Disease